GRIFOLS’ RED-FACED SHAREHOLDERS FINALLY SEE SOME GREENER PASTURES (BUY; 34% UPSIDE)
19/01/23 -" Amidst the volatile markets of the past two years, while Big Pharmas have materially outperformed – thereby regaining their safe-haven status - Smaller Pharmas have been out of favour due to both ..."
Pages
54
Language
English
Published on
19/01/23
You may also be interested by these reports :
11/11/26
The Q3 profitability materially surpassed expectations, backed by the strong momentum for migraine and depression/schizophrenia treatments. The ...
06/11/26
Genmab’s sales missed expectations, but profitability significantly exceeded expectations. Growth was driven by contributions from most offerings, ...
06/11/26
Sanofi’s growth in recent years has been single-handedly driven by its cornerstone immunology treatment Dupixent, though there has been some support ...
06/11/26
Novonesis delivered an in-line Q3 26, with revenue and adjusted EBITDA marginally ahead of consensus. Food & Beverages (F&B) accelerated to 14%, ...